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Abstract 
Introduction: Thyroid hormone autoantibody (THAAb) is one of the important 
factors affecting the measurement of thyroid function. By studying the results of a 
patient suffering with Hashimoto's thyroiditis, we fully communicated with the 
clinician, looked for reasons, and achieved the purpose of restoring the truth and 
 sorting out solutions [???]. 
Material and methods: During routine examination using an ADVIA-Centaur XP 
system, we found that the test of a case was inconsistent with her clinical 
manifestations, with abnormal elevation of free thyroxine (FT4) that did not conform
to the rule of the hypothalamic-pituitary-thyroid axis. Then, different platforms and 
demonstration of THAAbs with polyethylene glycol (PEG) precipitation were 
performed to eliminate the influence of THAAbs.
Results: The results showed that the thyroid function of the patient was consistent 
with the clinical manifestations and conformed to the law of the hypothalamic-
pituitary-thyroid axis using an Architect-i2000sr platform and Roche-Cobas-601 
system. The content of FT4 was significantly reduced and lower than the normal 
reference range after the patients' serum was treated with PEG, which was in line 
with the clinical practice. The serum THAAb titre of the patient was nearly 100 
times higher than that of the control group.
Conclusions: Once the thyroid function of the patients do not conform to their 
own laws and clinical manifestations [??], laboratory staff should consider the 
interference [??] of THAAbs. It is necessary to change the detection platform and 
retest the serum after PEG treatment while communicating with the clinicians, which
is of great significance to provide a true and accurate result to clinicians and patients.
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autoantibody; free thyroxine 4
Introduction
Autoantibodies are one of the many interferences [??]   in clinical practice [1], which
are often present in patients with autoimmune thyroid diseases. They directly target 
different antigens and exhibit nonspecific binding to markers in immunoassays. 
Thyroid hormone autoantibodies (THAAbs) affect the authenticity of thyroid 
hormone test results, leading to misdiagnosis or inappropriate treatment, and with 
unpredictable certain medical risks. The frequency of THAAbs is 1.8% in the 
healthy people [2], while the incidence is as high as 30–40% in patients with 
autoimmune thyroid disease [3, 4]. It is necessary to increasing the awareness of this 
type of analytical problem if laboratories are to avoid reporting incorrect test results. 
Here, we studied a patient with a falsely elevated test result due to the presence of 
serum THAAbs. We attempted to identify a method to correctly evaluate the thyroid 
function status in THAAb-positive patients.
Material and methods
Patient
A 61-year-old woman presented with fatigue and oedema for 4 years. She took 
methimazole because of detecting elevated free thyroxine (FT4) and thyroid-
stimulating hormone (TSH) levels in another hospital. The patient’s main 
manifestations were fatigue, weakness, chills, oedema, and constipation. After 
repeated examination, except the abnormal T4 and pituitary thyrotropin, the results 
of our hospital were consistent with the previous tests.
Analytical methods
Thyroid function tests (TFTs) [TSH, free triiodothyronine (FT3), and FT4] and the 
serum concentrations of total T3 and total T4 were measured by radioimmunoassay 
(RIA), chemiluminescence immunoassay on an ADVIA Centaur XP system and 
Architect i2000sr platform, and electrochemiluminescence immunoassay on a Roche
Cobas 601 system, respectively.
For the autoantibody binding test, radiolabelled T3 or T4 was added to the 
serum of a patient and the mixed serum of a normal subject. Subsequently, equal 
volumes of 25% polyethylene glycol (PEG) solution were added to the samples after
incubated for 2 h at 37 . Then, the mixture was centrifuged (4 , 10,000 rpm) for ℃ ℃
20 min, and the radioactivity of the precipitate was determined. The presence of 
antibodies against T3 or T4 was determined in accordance with the ratio of the count
of radioactivity to the total radioactivity (B/T). The concentrations of T3, T4, and 
TSH in the PEG-treated supernatant were determined.
Determination of THAAb
The patients’ serum samples and 20 normal subjects were added with radiolabelled 
T3 and T4 analogues. The titres of anti-T3 and -T4 autoantibodies were determined 
through RIA. Nonspecific binding was subtracted from all sample readings, and the 
final percentage of [125I] T4 or [125I] T3 binding was calculated. The result was 
expressed as the antigen-antibody binding rate.
Results
Comparison of thyroid function between different test platforms
The TFT of a patient diagnosed with Hashimoto's thyroiditis on the ADVIA Centaur 
XP system revealed increased serum FT4 and TSH, and reduced FT3. The results did
not conform to the hypothalamic-pituitary-thyroid axis and the clinical 
manifestations. Then, we tested TT3 and TT4 to identify the reason for this 
discrepancy. Surprisingly, the results were consistent with the laws of the 
hypothalamic–pituitary–thyroid axis and the clinical manifestations. Subsequently, 
we detected FT3\FT4\TSH through RIA and with the Architect i2000sr platform and 
Roche Cobas 601system. T3 and T4 levels were simultaneously detected by using 
the Architect i2000sr platform and Roche Cobas 601 system. The results were in 
accordance with regular rules. As shown in Table 1, the FT3 and TSH results from 
the four different detection systems show consistent trends, and the FT4 results are 
clinically consistent with the results of most platforms, except for the Siemens 
detection system.
Results of autoantibody binding experiment and TFT before and after PEG 
treatment
Specific binding to I125-T4 was observed in the patient’s serum. However, 
nonspecific binding to I125-T4 was also found in the serum of normal subjects. The 
former was 100-times higher than the latter. PEG precipitation is the most commonly
used immunosubtraction method and is widely accepted for the detection of 
macroprolactin [5] and analytes [6], although it is not perfect. Then, the serum of the
patient was precipitated by using PEG. TFT showed FT3 and TSH levels did not 
change significantly, whereas FT4 levels decreased significantly. These trends were 
consistent with the clinical manifestations of the patient (Tab. 2).
Patient's THAAb level
The THAAb titre of the patients was more than 100-times that of the control group. 
The mean value of the T3 antibody (%) in the normal control group was 2.1% and 
that in the patient was 4.7%, which was within the normal range. The mean value of 
the T4 antibody (%) in the normal control group was 0.5% and that in the patients 
was 59%, which was considerably higher than the normal level.
Discussion
Potential causes of spurious TFT results include nonspecific binding of endogenous 
circulating factors such as heterophilic antibodies, albumin variants, and THAAbs
[7]. THAAb, an analyte autoantibody specific to T4 and T3, is the only antibody 
reported to interfere with TFT. In theory, only one-step immunoassays are likely to 
be affected by THAAb interference. While the one-step assay is vulnerable to 
THAAs, which directly compete with endogenous free T4, a two-step assay 
employing an intermediate washing step induces a non-competitive reaction that 
removes the unbound free T4 and interfering factors. 
Some studies recommend PEG precipitation to eliminate the interference of 
THAAbs in serum TFT. As a simple method to remove immunoglobulin, PEG 
precipitation is important for improving immunoassay accuracy [8]. 
When TFT results are inconsistent in clinical testing, other methods for 
investigating immunoassay interference include the following: (a) demonstrating 
onlinear [nonlinear?] response to sample dilution; (c) demonstrating iodothyronine 
binding to the patient’s IgG through electrophoresis or precipitation with anti-IgG; 
(d) blocking heterophile antibodies with nonimmune serum or blocking tubes; and 
(e) suppressing patient antibodies with immunosuppressive therapy [9]. 
In this case, we confirmed immunoassay interference by repeating the analysis
on different platforms and demonstrating the presence of THAAbs through PEG 
precipitation. Antibody interference with serum free thyroxine must be considered 
when clinical findings and laboratory results show discrepancies. Prompt 
communication between clinicians and laboratory professionals can avoid 
unnecessary diagnostic procedures and treatments.
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RR — reference range; T3 — triiodothyronine; T4 — thyroxine; TSH — thyroid-
stimulating hormone
Table 2. Comparison of thyroid function test (TFT) results obtained with the 
Siemens ADVIA XP testing platform before and after polyethylene glycol (PEG) 
treatment
FT3 (pmol/L) FT4 (pmol/L) TSH (mIU/L)
Original serum 0.49 92.93 > 150
PEG-treated 
serum




FT3 — free triiodothyronine; FT4 — free thyroxine; TSH — thyroid-stimulating 
hormone
